<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04973722</url>
  </required_header>
  <id_info>
    <org_study_id>LY06006/CT-CHN-103</org_study_id>
    <nct_id>NCT04973722</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate LY06006 and Prolia in Healthy Adults</brief_title>
  <official_title>A Randomized, Double-blind, Parallel-group Study in Chinese Healthy Male Subjects to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of LY06006 Versus Prolia Following Single-dose Subcutaneous Injection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luye Pharma Group Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shan Dong Boan Biotechnology Co., Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Luye Pharma Group Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, parallel-group study in Chinese healthy male subjects to evaluate&#xD;
      the pharmacokinetics, pharmacodynamics, safety and immunogenicity of LY06006 versus Prolia&#xD;
      following single-dose subcutaneous injection&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design:&#xD;
&#xD;
      The study is a randomized, double-blind, parallel-group study in healthy adult male subjects&#xD;
      to evaluate the pharmacokinetics, pharmacodynamics, safety and immunogenicity of LY06006&#xD;
      versus Prolia following single-dose subcutaneous injection.&#xD;
&#xD;
      A total of 168 healthy male subjects will be randomized 1:1 to receive a single subcutaneous&#xD;
      (s.c.) injection of 60mg of either LY06006 ( LY06006 , 60 mg/1mL , Shandong Luye&#xD;
      Pharmaceutical Co., Ltd.) or Prolia (60 mg / 1 mL , Amgen Inc.). During the entire study&#xD;
      period, blood samples should be collected according to the Schedule of Assessments for&#xD;
      pharmacokinetic, pharmacodynamic and immunogenicity analysis, and safety assessments should&#xD;
      be conducted.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 9, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">April 10, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC 0- ∞</measure>
    <time_frame>168 days</time_frame>
    <description>Area under the concentration-time curve from time zero to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C max</measure>
    <time_frame>168 days</time_frame>
    <description>Maximum observed concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>s-CTX</measure>
    <time_frame>168 days</time_frame>
    <description>Percent change in serum s-CTX from baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUEC0-t</measure>
    <time_frame>168 days</time_frame>
    <description>The pharmacodynamic parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Emax</measure>
    <time_frame>168 days</time_frame>
    <description>The pharmacodynamic parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TEmax</measure>
    <time_frame>168 days</time_frame>
    <description>The pharmacodynamic parameters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vital signs：Temperature</measure>
    <time_frame>168 days</time_frame>
    <description>Safety measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs：pulse</measure>
    <time_frame>168 days</time_frame>
    <description>Safety measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs： blood pressure</measure>
    <time_frame>168 days</time_frame>
    <description>Safety measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs： respiration</measure>
    <time_frame>168 days</time_frame>
    <description>Safety measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination：general</measure>
    <time_frame>168 days</time_frame>
    <description>Safety measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination：head and neck region</measure>
    <time_frame>168 days</time_frame>
    <description>Safety measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination：lymph gland</measure>
    <time_frame>168 days</time_frame>
    <description>Safety measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination： oral cavity</measure>
    <time_frame>168 days</time_frame>
    <description>Safety measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination：chest</measure>
    <time_frame>168 days</time_frame>
    <description>Safety measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination：belly</measure>
    <time_frame>168 days</time_frame>
    <description>Safety measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination：Extremities and spine</measure>
    <time_frame>168 days</time_frame>
    <description>Safety measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination：nervous system</measure>
    <time_frame>168 days</time_frame>
    <description>Safety measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory tests：hematology</measure>
    <time_frame>168 days</time_frame>
    <description>Safety measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory tests：chemistry</measure>
    <time_frame>168 days</time_frame>
    <description>Safety measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory tests：urinalysis</measure>
    <time_frame>168 days</time_frame>
    <description>Safety measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory tests：parathyroid hormone</measure>
    <time_frame>168 days</time_frame>
    <description>Safety measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory tests：thyroid function</measure>
    <time_frame>168 days</time_frame>
    <description>Safety measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory tests：abdomen ultrasound</measure>
    <time_frame>168 days</time_frame>
    <description>Safety measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory tests：chest radiography</measure>
    <time_frame>168 days</time_frame>
    <description>Safety measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory tests：coagulation function</measure>
    <time_frame>168 days</time_frame>
    <description>Safety measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram (12-Lead ECG)</measure>
    <time_frame>168 days</time_frame>
    <description>Safety measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events(AEs)</measure>
    <time_frame>168 days</time_frame>
    <description>Safety measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADA</measure>
    <time_frame>168 days</time_frame>
    <description>The incidence and antibody titer of ADA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nab</measure>
    <time_frame>168 days</time_frame>
    <description>The incidence of Nab.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">168</enrollment>
  <condition>Healthy Adults</condition>
  <arm_group>
    <arm_group_label>LY06006</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg/1 ml, once every 6 months administered subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prolia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>60 mg/1 ml, once every 6 months administered subcutaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY06006</intervention_name>
    <description>60 mg/1 ml, once every 6 months administered subcutaneously</description>
    <arm_group_label>LY06006</arm_group_label>
    <other_name>subcutaneous injection of 60 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prolia</intervention_name>
    <description>60 mg/1 ml, once every 6 months administered subcutaneously</description>
    <arm_group_label>Prolia</arm_group_label>
    <other_name>Denosumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntarily signed the informed consent form;&#xD;
&#xD;
          2. Healthy males，ages ≥18 to ≤50 years;&#xD;
&#xD;
          3. Body weight ≥58 to ≤68 kg and Body mass index (BMI) &gt;18 to &lt;28 kg/m2, body mass index&#xD;
             (BMI) = weight ( kg ) / height 2 (m 2);&#xD;
&#xD;
          4. Normal or clinically acceptable vital signs, physical exams, laboratory tests, 12-&#xD;
             lead ECG, abdominal color Doppler ultrasound, chest radiograph, etc. screening;&#xD;
&#xD;
          5. No pregnancy plans and voluntarily take effective contraceptive measures from the&#xD;
             screening date to the end of the study .&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior diagnosis of bone disease, or any condition that will affect bone metabolism&#xD;
             such as, but not limit to: malignant tumors ( including myeloma ), hypoparathyroidism&#xD;
             / hyperthyroidism, hypothyroidism / hyperthyroidism, acromegaly, Cushing ' s syndrome,&#xD;
             hypopituitarism, severe chronic obstructive pulmonary disease, rheumatoid arthritis,&#xD;
             osteomalacia;&#xD;
&#xD;
          2. Prior history or current evidence of osteomyelitis or osteonecrosis of the jaw (ONJ),&#xD;
             or risk factors for ONJ such as invasive dental surgery or jaw surgery during the&#xD;
             trial, or unhealed dental or oral surgery wounds;&#xD;
&#xD;
          3. Recent bone fracture within 6 months;&#xD;
&#xD;
          4. Active and unhealed infections of the respiratory system, digestive system, urinary&#xD;
             system, reproductive system, or skin;&#xD;
&#xD;
          5. Serum calcium of &lt; Lower Limit of Normal (LLN) or &gt; Upper Limit of Normal (ULN);&#xD;
&#xD;
          6. Prior use of medications affecting bone turnover before screening and for the duration&#xD;
             of study, including but not limited to: denosumab, bisphosphonates or fluoride within&#xD;
             12 months, contraceptives containing estrogen, tibolone, estrogen, selective estrogen&#xD;
             receptor modulators, aromatase inhibitors, calcitonin, strontium salts, parathyroid&#xD;
             hormone (or derivatives), vitamin D supplements ( &gt;1000 IU/ day), anabolic steroids,&#xD;
             systemic glucocorticoids, calcitriol or similar, diuretics, anticonvulsants within 6&#xD;
             months; inhaled or topical glucocorticoid drugs within 2 weeks;&#xD;
&#xD;
          7. Allergy to more than two drugs or food, or allergy to the ingredients of the&#xD;
             investigational medicinal product (IMP);&#xD;
&#xD;
          8. Blood donation or massive blood loss ( ≥200 mL ) within 3 months before screening ;&#xD;
&#xD;
          9. Any vaccination within 6 months before screening or for the duration of study;&#xD;
&#xD;
         10. Prior use of any prescription drugs, over-the-counter drugs, any vitamin products or&#xD;
             herbal medicines within 14 days before screening ;&#xD;
&#xD;
         11. Intense physical exercise within 2 weeks before screening or for the duration of the&#xD;
             study, or any other conditions affecting drug absorption, distribution, metabolism,&#xD;
             and excretion;&#xD;
&#xD;
         12. Upon enquiry, prior smoke more than 5 cigarettes per day within 3 months before the&#xD;
             study;&#xD;
&#xD;
         13. Upon enquiry, a history of alcohol abuse ( drinking more than 14 units of alcohol per&#xD;
             week within the first three months prior to screening : 1 unit = 350 mL of beer, 45 mL&#xD;
             of liquor, or 150 mL of wine ), or positive alcohol test;&#xD;
&#xD;
         14. Positive urine screen for drug or a history of drug abuse or drug use in the past five&#xD;
             years upon questioning ;&#xD;
&#xD;
         15. Other diseases with clinical significance (such as nervous system, mental system ,&#xD;
             cardiovascular system, urinary system, digestive system, respiratory system, metabolic&#xD;
             endocrine system, blood system, skin disease, immune disease, tumor, etc.);&#xD;
&#xD;
         16. Any of the following tests positive: hepatitis B surface antigen ( HBsAg ), hepatitis&#xD;
             C antibody ( HCV-AB ), human immunodeficiency virus antigen antibody ( HIVAg / Ab )&#xD;
             and treponema pallidum antibody;&#xD;
&#xD;
         17. Acute diseases or concomitant medications from screening to IMP administration;&#xD;
&#xD;
         18. Consumption of any alcohol-containing products within 48 hours before administration&#xD;
             of the IMP ;&#xD;
&#xD;
         19. Prior participation in clinical trials for denosumab or denosumab biosimilar products;&#xD;
             current participation in other clinical studies, or receiving or have received any&#xD;
             investigational drug within 3 months (or less than 5-half lives of that medication,&#xD;
             whichever time period is longer) before receiving study drug ;&#xD;
&#xD;
         20. History of fainting blood or needles;&#xD;
&#xD;
         21. In the opinion of the investigator, others to be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guoping Yang, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Third Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Third Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 20, 2021</study_first_submitted>
  <study_first_submitted_qc>July 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Compare</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Safety</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>LY06006</keyword>
  <keyword>Prolia</keyword>
  <keyword>Healthy Adults</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

